Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV.
Novello S, et al. Among authors: reck m.
Ann Oncol. 2022 Apr;33(4):454. doi: 10.1016/j.annonc.2022.01.005. Epub 2022 Jan 25.
Ann Oncol. 2022.
PMID: 35086737
Free article.
No abstract available.